Abstract: A compound represented by the following formula (a): CH2?CR1—CONJ-CKR2—(CH2)n—COO-Q1-Rf1??(a) is provided. This compound is capable of forming a polymer having an oil repellency equivalent to polymers containing a polyfluoroalkyl group containing at least 8 carbon atoms, although the polyfluoroalkyl group contains up to 6 carbon atoms. In the formula, R1 is hydrogen atom or methyl group, R2 is hydrogen atom or a group represented by —(CH2)m—COO-Q2-Rf2 (r), n and m are independently an integer of 0 to 4, Rf1 and Rf2 are independently a polyfluoroalkyl group or a polyfluoroether group containing 1 to 6 carbon atoms, Q1 and Q2 are independently single bond or a divalent linkage group, J is hydrogen atom or an alkyl group containing 1 to 3 carbon atoms, K is hydrogen atom or an alkyl group containing 1 to 3 carbon atoms, and j and k are independently single bond or an alkylene group containing 1 to 3 carbon atoms with the proviso that j and k are not simultaneously single bond.

Abstract: Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions comprising prodrugs of methyl hydrogen fumarate, and methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis are disclosed.

Abstract: A process is proposed for the preparation of a powder comprising one or more derivatives of glycine-N,N-diacetic acid and/or one or more derivatives of glutamine-N,N-diacetic acid with a degree of crystallinity of ?30%, starting from an aqueous solution comprising the one or more derivatives of glycine-N,N-diacetic acid and/or the one or more derivatives of glutamine-N,N-diacetic acid in a concentration range from 20 to 60% by weight, based on the total weight of the aqueous solution, where the aqueous solution is concentrated in a first process step in an evaporator with rotating internals, which are arranged at a distance relative to the inside wall of the evaporator of ?1% of the diameter of the evaporator, to give a crystal slurry with a solids concentration in the range from 60 to 85% by weight, based on the total weight of the crystal slurry, and where in a second process step the crystal slurry is left to ripen in a paste bunker and then in a thin-film contact dryer, and where the residence time in t

Abstract: The present invention relates to the use of an alkoxylate based on 2-propylheptylamine which has been alkoxylated with ethylene oxide, propylene oxide, butylene oxide, pentylene oxide, styrene oxide, cyclohexylene oxide and/or decylene oxide, and/or its quaternized derivative in cleaning compositions, as emulsifier, in the manufacture of fibers, for leather treatment, in printing inks, in formulations for construction chemistry or in formulations for flotation. Furthermore, the present invention relates to a mixture comprising at least one of the specified alkoxylates and also at least one surface-active substance and use thereof.

Abstract: The invention discloses a number of therapeutic compounds and a method of treating a disorder in mammal.

Abstract: The present disclosure provides analogs and derivatives of phorbol compounds for the treatment of viral infections, neoplastic diseases, inflammatory reactions, and use as analgesics.

Abstract: The presently disclosed subject matter provides compounds of the formula, formula (Ia): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, X, Y, and n are as defined herein. Also disclosed are methods for making the compounds of the formula as set forth hereinabove, their use in inhibiting acid ceramidase and ceramidase-related activity, and their use as drugs and prodrugs in the treatment and/or prevention of diseases associated with undesirable ceramidase or sphingosine kinase activity, including, but not limited to, cancer, cancer metastasis, atherosclerosis, stenosis, inflammation, asthma, and atopic dermatitis.

Abstract: The present invention relates to a novel process for the preparation of ?-amino acids, such as (±)-3-(aminomethyl)-5-methyl-hexanoic acid (1), which is a key intermediate in the preparation of the potent anticonvulsant pregabalin, (S)-(+)-3-(aminomethyl)-5-methyl-hexanoic acid (2), and its analogues.

Abstract: What is described are the compounds and the synthesis of [F-18]-labelled L-glutamic acid, [F-18]-labelled L-glutamate, their derivatives of the formula (I) and their use.

Abstract: An object of the present invention is to provide dermatological agents such as whitening agents and hair growth accelerators that contain a compound having high water solubility and a specific structure capable of releasing 2,3-dimethoxy-5-methyl-1,4-dihydroxybenzene (reduced form). A dermatological agent according to the present invention contains a 2,3-dimethoxy-5-methyl-1,4-dihydroxybenzenecarboxylic acid ester derivative represented by the following general Formula (I) or a salt thereof: wherein in the Formula (I), R1, R2 and R3 are specific groups.

Abstract: Nitrogen-containing lipids prepared from the conjugate addition of amines to acrylates, acrylamides, or other carbon-carbon double bonds conjugated to electron-withdrawing groups are described. Methods of preparing these lipids from commercially available starting materials are also provided. These amine-containing lipids or salts forms of these lipids are preferably biodegradable and biocompatible and may be used in a variety of drug delivery systems. Given the amino moiety of these lipids, they are particularly suited for the delivery of polynucleotides. Complexes or nanoparticles containing the inventive lipid and polynucleotide have been prepared. The inventive lipids may also be used to in preparing microparticle for drug delivery. They are particularly useful in delivering labile agents given their ability to buffer the pH of their surroundings.

Abstract: Described herein are methods for treating lack of hair growth or a reduction or loss of existing hair by stimulating and/or restoring hair growth, or preventing hair loss. The methods comprise administering to a subject in need thereof a therapeutically effective amount of a fullerene.

Abstract: This invention relates to cationic lipids. More particularly the invention relates to biodegradable cationic lipids having a plurality of cationic headgroups and one or more lipophilic tail groups. The lipids are of utility in various applications, and in particular in permitting transfection of molecules, and in particular DNA and RNA, into cells. As such the lipids have specific utility in the field of gene therapy as well as other applications such as delivery of small molecules into cells, detergents, and metal ion complexation for medical or industrial applications.

Abstract: The invention relates to a PEGylated peptide-chromophore conjugate, which forms irregular micelles, for use in photodiagnostic and phototherapeutic applications. Methods for synthesizing and using the conjugates of the invention are also provided.

Abstract: Materials and Methods for preparing (S)-(+)-3-aminomethyl-5-methyl-hexanoic acid and structurally related compounds via enzymatic kinetic resolution are disclosed.

Abstract: An additive for oils that is capable of imparting oils such as lubricant base oils or fuel oils with superior wear resistance properties or superior friction resistance properties and the like are provided. The additive for oils comprising a compound represented by formula (I): [Chemical Formula 1] (A)m-W—(B)n ??(I) wherein m represents an integer of 0 to 4, n represents an integer of 2 to 6, A represents hydroxy or amino, W represents hydrocarbon or the like, and B represents formula (II): wherein a represents 0 or 1, X represents an oxygen atom or NH, Y represents OR1 or NHR2 (wherein R1 and R2 each represent alkyl optionally having one or more substituents or the like), and Z1 and Z2 each represent a hydrogen atom, NR3R4 (wherein R3 and R4 each represent alkyl optionally having one or more substituents or the like) or the like, and the like are provided.

Abstract: A novel class of hydroxylases is described having the amino acid sequence of SEQ ID NO: 2, 4, 6 and 8, and variants and fragments thereof having HIF hydroxylation activity. The polypeptides of the invention have in particular prolyl hydroxylase activity. An assay method monitors the interaction of the HIF hydroxylase with a substrate. Modulators of HIF hydroxylase are provided for use in the treatment of a condition associated with increased or decreased HIF levels or activity or for the treatment of a condition where it is desirable to modulate HIF levels or activity.

Abstract: A dispersible carbon nanotube (“CNT”) comprising a CNT backbone and an organic moiety attached to the carbon nanotube backbone and comprising a hydroxyl substituted C6 to C14 aromatic group are described, as well as a CNT-polymer composite and a method of manufacturing the CNT-polymer composite.

Abstract: The present invention provides an amphiphilic molecule having a plurality of zwitterionic functional groups in its hydrophilic moiety and a molecular assembly comprising the amphiphilic molecule as a constituent lipid. According to a preferred embodiment of the present invention, the molecular assembly of the present invention forms a stable vesicular structure under a physiological pH environment to carry a substance of interest in the vesicular structure, and can release the substance of interest to the outside of the vesicular structure when it is deformed under an acidic pH environment. The molecular assembly of the present invention can be used as a carrier for a drug, a probe, a nucleic acid, a protein or the like.

Abstract: This invention relates to dialdehyde or dinitrile compounds, which are useful for stereoselective synthesis of piperidine, pyrrolidine, and azepane derivatives.

Abstract: A novel use of conjugates of psychotropic drugs (e.g., antidepressants or anti-epileptic drugs) and organic acids such as GABA in the treatment of pain is disclosed. A novel GABA conjugate and uses thereof is also disclosed.

Abstract: A dendritic compound of the following structure: PDn-Z-L is disclosed. In the structure above, P is X—(CH2CH2—O)r—, r is an integer ranging from 1000 to 4000, X is OH, NH2, or OR, R is C1 to C10alkyl, Dn is a residue of branched C3 to C30 polyol compounds, n is the quantity of layers of the residue of branched compounds and is an integer equal to or greater than 1, L is a metal cation, Z is the residue of a C3 to C30 compound with multi functional groups. The functional groups illustrated above can be carboxylic groups, amino groups, amide groups, or chelating groups. The carboxylic groups, ester groups, amino groups, or amide groups bind to Dn, and the chelating groups bind to the metal cations.

Abstract: The present invention relates to new hyperbranched polyesters based on oligohydroxycarboxylic acids with defined functionality.

Abstract: A composition and a method for administering the composition to a patient in order to accelerate wound healing, particularly postoperative wound healing. The composition, which essentially comprises ornithine ?-ketoglutarate, is water-soluble and formulated for oral administration in single-dose packets. The method for using the composition for promoting wound healing includes the step of administering the composition to a patient preoperatively as well as-postoperatively in accordance with a prescribed protocol. The composition may be customized to include one or more additional agents that are effective for promoting nutritional health and/or treating a particular medical problem. The composition may also be taken daily by athletes to minimize the healing time of closed wounds such as muscle or tendon tears that occur during participation in sports, even when the symptoms of such injury are subclinical.

Abstract: Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions comprising prodrugs of methyl hydrogen fumarate, and methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis are disclosed.

Abstract: A method of is provided for producing optically active ?-amino acid benzyl esters. The method includes reacting an optically active ?-amino acid and benzyl alcohols in the presence of an acid, wherein the reaction is carried out under reduced pressure without substantially using a solvent, while distilling off water generated by the progress of the reaction.

Abstract: The invention provides a developer and a processing method for a light sensitive planographic printing plate material (also referred to simply as a planographic printing plate material) providing excellent contamination resistance during printing and high reproduction of dot and line images.

Abstract: A method for forming cascade polymers specifically utilizing the amine monomer of the formula The monomer is made by initially reacting nitromethane and CH2?CHCO2— TBu by nucleophilic addition to form the triester nitrotrialkanoate of the formula and then reducing the nitrosubstituent to afford the said amine monomer.

Abstract: The synthesis and characterization of polymer core initiators are described herein. Polymer core initiators are used to prepare the polyfunctional prepolymers described herein, which may be optionally tethered. The polyfunctional prepolymers described herein are used to prepare cements, optionally with added co-monomers, for repairing and restoring tissues.

Abstract: Amphoteric compounds are described, having a zwitterionic structure of the betainic type having general formula (I) and their use for the control of phytopathogen fungi and/or the mitigation of abiotic and biotic stress.

Abstract: A polymer film includes: a wavelength dispersion regulator represented by formula (I): wherein R1 and R2 each independently represents a hydrogen atom, an alkyl group or an aryl group, provided that both R1 and R2 are not hydrogen atoms at the same time; and R3 and R4 each independently represents an electron-withdrawing substituent, and R1 and R2, or R3 and R4 may be bonded together to form a ring, and wherein the polymer film has a retardation value that satisfies the following formulae (1) and (2): 70 nm?Rth(548)?300 nm??Formula (1) Rth(628)<Rth(548)<Rth(446)??Formula (2) wherein Rth(?) represents a retardation value expressed in nm in a film thickness direction measured at a wavelength of ? nm.

Abstract: The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce ?Gal epitopes or ?Gal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-?Gal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.

Abstract: Materials and Methods for preparing (S)-(+)-3-aminomethyl-5-methyl-hexanoic acid and structurally related compounds via enzymatic kinetic resolution are disclosed.

Abstract: According to the present invention, a process is provided for producing an acyl group-containing composition that includes a step of reacting a long chain N-acyl acidic amino acid anhydride with one or more compounds which have, per molecule, m functional groups of one kind or more selected from the group consisting of hydroxyl, amino and thiol groups in an aqueous solvent and/or a mixed solvent of water and an organic solvent (reaction step). The process makes it possible to produce an acyl group-containing composition that is free from coloration under moderate conditions.

Abstract: An ionic liquid is disclosed A precursor composition that comprises at least one ionic liquid and at least one energetic material is also disclosed, as is a method of synthesizing an ionic liquid and a method of desensitizing an explosive composition.

Abstract: This invention relates to newly identified ester-linked Gemini surfactant compounds of formula (I), where Y is either H or (Aa)x where (Aa) is a basic amino acid and x is 1 to 6, to the use of such compounds and to their production. The invention also relates to the use of the ester-linked Gemini surfactant compounds to facilitate the transfer of polynucleotide into cells.

Abstract: The present invention relates to compounds particularly asymmetric urea compounds which are labeled with one or more radioisotopes and which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors which express NAALADase and/or PSMA. In another embodiment, the invention relates to methods of imaging tissues, organs, or tumors using radiolabeled compounds of the invention, particularly tissues, organs, or tumors which express NAALADase and/or PSMA to which the compounds of the invention have an affinity.

Abstract: Surfactants of formula (I) wherein each R is independently hydrogen or a C1 to C4 alkyl group; A is independently hydrogen or —C(O)—O—B; Ro is a linear, branched or cyclic aliphatic group, or combination thereof, having from about 2 to about 100 carbon atoms, interrupted or substituted by 1 to about 50 hydrophilic groups, said hydrophilic groups selected from the group consisting of hydroxyl, amino, ether and mixtures thereof; wherein specific ratios of and bonding of hydrophilic groups to carbon atoms is required; each B is independently of specific formulae containing perfluoroalkyl and —S(CH2)t—, and m, d, n, and t are 0 or integers with specific limitations.

Abstract: The invention concerns compounds of formula (1) wherein in particular G represents the —N(CH3)2—, —N(C2H5)2-group or N-pyrrolidine: n is an integer equal to 1 or 2: R1, R2 and R3, independently of one another, represent a hydrogen atom or a methyl group, the successive unsaturated units capable of being moreover identical or different, provided that at least one of the substituents R1, R2 and R3 is different from H: and Y1 and Y2 represent each a —COOCH3 group or a COOC2H5 group.

Abstract: The present invention provides polymeric compounds that can form micelles in solutions. These compounds have a hydrophobic, core that is coupled to a plurality of hydrophilic moieties.

Abstract: A method for forming cascade polymers specifically utilizing the amine monomer of the formula The monomer is made by initially reacting nitromethane and CH2?CHCO2-TBu by nucleophilic addition to form the triester nitrotrialkanoate of the formula and then reducing the nitrosubstituent to afford the said amine monomer.

Abstract: The invention concerns compounds of formula (1) wherein in particular G represents the —N(CH3)2—, —N(C2H5)2-group or N-pyrrolidine: n is an integer equal to 1 or 2: R1, R2 and R3, independently of one another, represent a hydrogen atom or a methyl group, the successive unsaturated units capable of being moreover identical or different, provided that at least one of the substituents R1, R2 and R3 is different from H: and Y1 and Y2 represent each a —COOCH3 group or a —COOC2H5 group.

Abstract: The invention concerns compounds of formula (1) wherein in particular G represents the —N(CH3)2—, —N(C2H5)2— group or N-pyrrolidine: n is an integer equal to 1 or 2: R1, R2 and R3, independently of one another, represent a hydrogen atom or a methyl group, the successive unsaturated units capable of being moreover identical or different, provided that at least one of the substituents R1, R2 and R3 is different from H; and Y1 and Y2 represent each a —COOCH3 group or a —COOC2H5 group.

Abstract: Provided is a zwitterionic lipid compound represented by formula (I) given below: In formula (I), m and n are independently integers of 1 to 4, p is an integer of 7 to 21, one R is NH3+, and each other R is H.

Abstract: The present invention is directed to novel dipeptides thereof, represented by the general Formula I: where R1-R3 and AA are defined herein. The present invention relates to the discovery that compounds having Formula I are potent inhibitors of apoptotic cell death. Therefore, the inhibitors of this invention can retard or block cell death in a variety of clinical conditions in which the loss of cells, tissues or entire organs occurs.

Abstract: The present invention is directed to a method for producing amino acids by reacting halogenated carboxylic acid ester (haloacid esters) with a metal cyanate in the presence of an alcohol and by subsequent acidic saponification of the urethane carbonic acid formed. The method is characterized by the metal cyanate being placed at an elevated temperature in an organic solvent and the other reactants being continuously charged into the mixture over a defined time period.

Abstract: The instant invention provides reagents and methods for diagnosis, detection and treatment of cancers (for example, prostate cancers). In particular, the invention provides methods to generate various functionalized PSMA ligands, and their uses in diagnosis, detection, imaging, and treatment of prostate cancers, especially those overexpressing PSMA.

Abstract: The present invention is directed to an analytical method for measuring the concentration of an N-(phosphonomethyl)iminodiacetic acid (“NPMIDA”) substrate, an N-(phosphonomethyl)glycine product, formaldehyde, formic acid, N-methyl-N-(phosphonomethyl)glycine (“NMG”), N-methyl-aminomethylphosphonic acid (MAMPA) or aminomethylphosphonic acid (“AMPA”)) in an aqueous mixture thereof, using infrared spectroscopy. The present invention is also directed to a process for oxidizing an N-(phosphonomethyl)iminodiacetic acid substrate to form a N-(phosphonomethyl)glycine product, and as part of the process, measuring the concentration of at least one reactant, product or byproduct of the oxidation reaction using the analytical method of the present invention and controlling the oxidation process in response to the measurement taken.

Abstract: Stereoselective process for the industrial synthesis of compounds of formula (I): wherein R represents linear or branched (C1-C6)alkyl. Application in the synthesis of perindopril and pharmaceutically acceptable salts thereof.

Abstract: The present invention relates to polyaspartate mixtures containing a) 5 to 50 equiv. %, based on the total equivalents of aspartate groups, of a polyoxypropylene polyaspartate corresponding to the formula wherein X1 represents the residue obtained by removing the amino groups from a polyoxypropylene polyamine having a functionality of n, R1 and R2 are identical or different and represent organic groups which are inert to isocyanate groups at a temperature of 100° C. or less, R3 and R4 are identical or different and represent hydrogen or organic groups which are inert towards isocyanate groups at a temperature of 100° C. or less and n is 2 to 4, and b) 50 to 95 equiv.